Mutazioni di HBV in corso di trattamento; quale approccio razionale?
|
|
- Amanda McDowell
- 6 years ago
- Views:
Transcription
1 Mutazioni di HBV in corso di trattamento; quale approccio razionale? Prevenire Interpretare Trattare Marco Lagget UODU Gastroenterologia ed Epatologia AOU San Giovanni Battista di Torino
2 Prevenire 1) Timing
3 Indication to Treatment is an Integrated Decision LIVER DISEASE STAGE HBVDNA LEVELS INDICATION TO TREATMENT PATIENT PROFILE PREVENTION OF HBV DRUGS RESISTANCE EASL 2009, Stresa 1-2
4 EASL Stresa 1
5 Preventire: 2) strategie terapeutiche Short-term: trattamento curativo IFN (S2)/ NUC (S3) Follow-up (mesi/anni) Risposta Durante il trattamento Anti-HBe+ HBV DNA < 2000 UI/ml ALT < UNL Portatore inattivo (PCI) Perdita HBsAg NUC (s) Long-term: trattamento soppressivo HBV DNA < 200 UI/ml Prtatore inattivo (PCI) Perdita HBsAg Anni
6 Prevenire: 3) scelta del farmaco Nucleoside analogue - Lamivudine - Entecavir - Telbivudine - Emtricitabine Trade name Company Dosage * 2007 ZEFFIX 100 mg/die 89 BARACLUDE 0.5mg/1mg/die 670 SEBIVO* 600 mg/die 693 EMTRIVA ^ 200 mg/die 266 Nucleotide analogue - Adefovir Dipivoxil HEPSERA 10 mg/die Tenofovir Disopr. Fum. VIREAD 300 mg/die 415 Nucleoside+nucleotide analogue - Emtricitabine + TRUVADA ^ 200 mg+ 713 Tenofovir Disopr. Fum. 300 mg/die ^ Drug approved for HIV *
7 HBeAg-Positive naive Patients 48 weeks HBe seroconversion Undetectable HBV DNA Normal ALT 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 30% 22% 12% 22% 26% 21% 25% 39% 21% 67% 60% 74% 39% 66% 48% 68% 77% 69% 0% PEG-IFN LAM ADV ETV LdT TDF PEG-IFN LAM ADV ETV LdT TDF PEG-IFN LAM ADV ETV LdT TDF EASL 2009
8 Dec Mean HBV DNA: 8.64 (TNF) vs 8.88 (ADV) Logs Jan Mean HBV DNA: (ETV) vs 9.88 (ADV) Logs 76% 58%
9 Entecavir
10 ( LAM ) HBeAg seroconversion: 31% (ETV) vs 26%
11 Entecavir Risposta in pazienti HBeAg+ ( anni (naïve, 5 ETV-022 HBeAg(+) ETV Long-term Cohort (ETV-022 ETV-901) Proportion of Patients (%) HBV DNA <300 copies/ml Year 1 67% Year 1 55% Year 2 83% Year 3 89% Year 4 91% Year 5 94% 0 n = 236/354 80/ / /131 98/108 88/94 a a 5 patients who remained on treatment at the Year 5 visit had missing PCR values (NC=M) Han, AASLD 2008
12 HBV DNA suppression HBeAg(+) ETV Long-term Cohort (ETV-022 ETV-901) Mean HBV DNA (log 10 copies/ml) copies/ml HBV DNA Suppression 0 0 Year 1 Year 2 Year 3 Year 4 Year 5 n = a a 5 patients who remained on treatment at the Year 5 visit had missing PCR values (NC=M) Han, AASLD 2008
13 Resistance Analysis One (0.7%) of the 146 patients in this cohort had ETV resistance (Year 3). This patient also experienced virologic breakthrough Among the 47 patients who discontinued ETV prior to the Year 5 visit, 10 patients (7%) had HBV DNA 300 copies/ml at the last on-treatment measurement Genotypic analysis showed that none had evidence of genotypic ETVr Safety Good, no renal disfunction Han, AASLD 2008
14 Lactic acidosis (LA) and NUC
15 HBeAg-Negative naive Patients 48 weeks Undetectable HBV DNA Normal ALT 100% 90% 80% 70% 60% 50% 40% 63% 72% 51% 90% 92% 88% 38% 78% 77% 74% 72% 74% 30% 20% 10% 0% PEG-IFN LAM ADV ETV LdT TDF PEG-IFN LAM ADV ETV LdT TDF EASL 2009
16 3-yr ETV in HBeAg-negative Re-Treatment cohort Virological response ETV-027 ETV-901 Proportion of patients (%) HBV DNA <300 copies/ml % Off-treatment >60 days 93% 94% 95% 91% 83% 59% 4% EOD Baseline Wk 12 Wk 24 Wk 48 Wk 72 Wk 96 Wk 144 n= 93/99 4/99 56/95 79/95 84/90 72/77 67/74 54/57 EOD= end-of-dosing 10 patients who remained on treatment at the Week 144 of ETV-901 visit had missing PCR samples Shouval, AASLD 2008
17 Tenofovir
18 2:1 RCTs HBeAg + (176 pts-5 LAM exp) and (250 pts-43 LAM exp) TNF vs HBeAg + (90 pts-1 LAM exp) and (125 pts-23 LAM exp) ADV for 48 weeks HBV DNA negative (< 400 cps/ml/69 IU/mL) Assay: TaqMan cut-off 29 IU/mL HBeAg+ 76% TNF and 13% ADV HBeAg- 93% TNF and 63% ADV (P<0.001) Mean HBV DNA HBeAg LOG Mean HBV DNA HBeAg LOG
19 Two Years Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) (ITT) Switch Data in HBeAg+ (Heathcote J) and anti-hbe+ (Marcellin ( P Three years (HBeAg+ and anti-hbe+ ITT 81%; OTA 97%), Lee, AASLD 2009 D o u b l e B li n d Y e a r 1 O p e n - l a b e l Y e a r 2 Y e a r 8 RANDOMIZATION 2:1 T e n o f o v i r m g A d e f o v i r 1 0 m g T e n o f o v i r m g T e n o f o v i r m g P r e - t r e a t m e n t L i v e r B i o p s y W e e k 4 8 L i v e r B i o p s y W e e k 7 2 * W e e k 9 6 W e e k Patients With HBV DNA <400 copies/ml (95% CI) (ITT) Patients with HBV DNA <400 copies/ml (95% CI) (ITT) 100 TDF-TDF ADV-TDF Percentage (%) n= n= Randomized Double Blind Open Label Weeks in Study % 78% P=0.801 Percentage (%) Randomized Double Blind Weeks on Study Open Label TDF-TDF N= ADV-TDF N= % P= % 18% LAM Exp: 93% 96% Heathcote J, AASLD 2008 Marcellin, P, AASLD 2008
20 Resistance Surveillance Results No resistance up to 2 years of TDF mono-therapy No HBV pol/rt amino acid substitutions associated with TDF resistance were detected through 96 weeks of TDF monotherapy Safety Good, no renal disfunction
21 Prevenzione: 4) aderenza ai criteri di risposta Primary non-response Less than 1 log 10 IU/mL decrease in HBV DNA level from baseline at 3 months of therapy Virological response Partial virological response Virological breakthrough Undetectable HBV DNA by real-time PCR assay (<10-15 IU/mL) within 48 weeks of therapy Decrease of HBV DNA of more than 1 log 10 IU/mL but detectable HBV DNA by real-time PCR at 24 or 48 weeks of therapy (according to drug potency and genetic barrier to ( resistance Confirmed increase in HBV DNA level of more than 1 log 10 IU/mL compared to the nadir HBV resistance to NUCs Selection of HBV variants with amino acid substitutions that confer reduced ( NUC(s susceptibility to the administered EASL 2009
22 Partial virologic response to NUCs (%) and risk of resistance Resistance rate % LdT LAM 39% ADV 49% % 1% 6% 13% 7% 25% 20% % 0 <QL QL-3 log 3-4 log >4 log 0 <3 log >3 log HBV DNA at week 24 HBV DNA at week 48 Lai et al AASLD 2005 Hadziyannis et al, Gastroenterology 2006
23 Terapia di prima linea con analoghi nucleos(t)idici ( PVR ) Risposta virologica parziale settimane 48 settimane * 16% 72w ^ 22% 72w * 6% 72w ^ 1-9 % 72w HBeAg+ HBeAg+ % PVR % Anti-HBe+ 87% Anti-HBe+ 69% 20% 29% 33*% 24^% 37% 10*% 8^% LDT LAM ADV ETV TNF
24 Prevenzione: 4) aderenza ai criteri di risposta Primary non-response Less than 1 log 10 IU/mL decrease in HBV DNA level from baseline at 3 months of therapy Virological response Partial virological response Virological breakthrough Undetectable HBV DNA by real-time PCR assay (<10-15 IU/mL) within 48 weeks of therapy Decrease of HBV DNA of more than 1 log 10 IU/mL but detectable HBV DNA by real-time PCR at 24 or 48 weeks of therapy (according to drug potency and genetic barrier to ( resistance Confirmed increase in HBV DNA level of more than 1 log 10 IU/mL compared to the nadir HBV resistance to NUCs Selection of HBV variants with amino acid substitutions that confer reduced ( NUC(s susceptibility to the administered EASL 2009
25 Cumulative Incidence of HBV Resistance in naive patients 100% 90% Year 1 Year 2 80% 70% 70% 67% Year 3 Year 4 Year 5 60% 50% 49% 40% 38% 30% 20% 24% 18% 29% 22% 10% 0% LAM 3% 0% 11% ADV 0.5% 1.2% 4% 0.2% 1.2% 1.2% 0% ETV LdT TDF EASL 2009
26 Long-Term Treatment with NUCs suppressive strategy Indicated in HBeAg-positive patients who achieve an HBe seroconversion did not HBeAg-negative patients The most potent drugs with the optimal resistance profile should be used as first-line monotherapies: Tenofovir Entecavir EASL 2009
27 Interpretare Keefee, J Vir Hep 2009 Marzano, 2007
28 Trattare la resistenza: Switch-to o Add-on
29 Add-on vs switch-to strategy ( 3y ) in 588 e-chb LAM-R patients 100 % Patients with HBV DNA < 3 log cp/ml % P< % 0 ADV mono ADV+LAM Lampertico & Marzano, AASLD 2006
30 Add-on vs. switch-to strategy ( Logs in 42 LAM-R patients (HBV DNA > 5 % Patients with HBV DNA < 3 log cp/ml % ADV mono ( 21 ) P< % ADV+LAM (21) Gaia & Marzano, J Hepatol 2008
31 Add-on versus switch-to ADV in ( resistance LAM-R HBeAg- CHB (ADV Patients with ADV-R (%) A randomized controlled study 30% ADV mono (n=265) P<0.05 6% ADV+LAM (n=272) Lampertico & Marzano AASLD 2006
32 Lamivudine-Refractory Cohort (HBeAg+): Cumulative Probability of ETV Resistance Through 5 Years 100% ETVr = LVDr (M204V ± L180M) + T184, S202 and/or M250 substitutions ETVr + Virologic Breakthrough ( 1( 1 log increase from nadir) Cumulative Probability (%) 75% 50% 25% 0% Years N= N= N= N= N=33 72/187 (39%) achieved HBV DNA < 300 c/ml; 3/72 (4%) had subsequent genotypic ETV resistance
33
34 Detection of Mutations Associated With Resistance to Nucleos(t)ide Analogues in Patients With HBV Infection During Treatment With Tenofovir P r o b a b ilit y o f A c h ie v in g H B V D N A le v e ls < c o p ie s /m L w it h T e n o f o v ir M o n o t h e r a p y in H B V - m o n o in fe c t e d P a tie n t s A c c o r d in g t o t h e P r e s e n c e o f R e s is t a n t V a r ia n ts P < P a tie n ts u n d e r o b s e r v a tio n m o n th s W t L V D -R A D V -R K a p la n -M e ie r A n a ly s is ; P < , lo g ra n k. W t: w ild ty p e ; L V D : la m iv u d in e ; A D V : a d e fo v ir d ip iv o x il Van Bommel, AASLD 2008
35 Add-on strategy 3-4 yrs ADV+LAM treatment in 145 LAM-R pts: virological response and ADV resistance Years of treatment (1) Virologicalresponse (n=145) (n=112) (n=78) (n=39) HBV-DNA <35 cp/ml (2) 86 (61%) 78 (70%) 62 (79%) 32 (82%) Virologic breakthrough (3) Genotypic ADV-R (4) rta181t (5) 1 (0.7%) 1 (0.9%) 1 (1.3%) 0 (1) Median follow-up: 42 months (range 12-76) (2) TaqMan real time PCR assay, LLQ: 1.5 log copies/ml (3) > 1 log HBV-DNA compared to on treatment nadir, tested every 3 months (4) rtn236t and rta181v by INNOLiPA V2 assay (5) as a mixed viral population with rta181a Lampertico et al, Gastroenterology 2007
36 Early vs late treatment in LAM-R patients Cumulative virologic response by baseline viremia in 52 subjects 1,0 < 4 log HBV DNA %,8 4-5 log HBV DNA >5 log HBV DNA p<0,05 p< 0,0001,6,4,2 0, Months Uni and Multivariate analysis: Basal HBV DNA load ( p<0.001,rr3.8,ci 95% ) and HBeAg+ (p<0.01, RR 3.6, CI 95% status ) predicted VR. Basal ALT, age, sex, serum creatinine, stage of disease, therapeutic strategies: did not predict VR at univariate analysis. Gaia & Marzano, J Hepatol 2008
37 In vitro Tenofovir sensitivity of HBV populations from clinical specimens containing rta181t/v and or rt236t The presence of 50% of rta181t/v and/or N236T mutations did not have an impact of TNF susceptibility in an in vitro phenotypic assay ( 434 ) Kitrinos Km et al., AASLD 2009
38 Management of HBV Resistance Lamivudine resistance Add tenofovir Telbivudine resistance Add tenofovir* Entecavir resistance Adefovir resistance Tenofovir resistance** Add tenofovir* Switch to tenofovir and add a second drug If N236T, add lamivudine, entecavir* or telbivudine* or switch to Truvada If A181V/T, add entecavir* or switch to Truvada Do genotyping and phenotyping in an expert lab to determine the cross-resistance profile Add entecavir*, telbivudine*, lamivudine or switch to Truvada Nucleoside Nucleotide *the long-term safety of these combinations is unknown **not seen so far EASL 2009
39 2010 and more.challenge Partial Virological Response and Resistance Check for compliance Resistance surveillance and knowledge Patients receiving lamivudine, adefovir or telbivudine with a partial virological response at week 24: Either change to a more potent drug (tenofovir or ( entecavir Or add a more potent drug that does not share crossresistance Patients receiving tenofovir or entecavir with a partial virological response at week 48: Add the other drug in order to prevent resistance in the long term
HBV Therapy in Special Populations: Liver Cirrhosis
HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationIs there a need for combination therapy? No. Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain
Is there a need for combination therapy? No Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain No, No and No EASL Update HBV Guidelines 2012 The most potent drugs with the optimal
More informationHBeAg-negative chronic hepatitis B. with a nucleos(t)ide analogue?
4 th PARIS HEPATITIS CONFERENCE HBeAg-negative chronic hepatitis B Why do I treat my chronic hepatitis B patients with a nucleos(t)ide analogue? George V. Papatheodoridis, MD 2nd Department of Internal
More informationAcute Hepatitis B Virus Infection with Recovery
Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis
More informationThe Goal of HBV Therapy. Key Points. The Twin Pillars of HBV Therapy
How to Follow Once You tart Hepatitis B Treatment And When To Worry About esistance American College of Gastroenterology October 16, 21 ra Jacobson, MD Vincent Astor Professor of Medicine Chief, Division
More informationEntecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naïve Patients
Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naïve Patients D.J. Tenney 1, K.A. Pokorowski 1, R.E. Rose 1, C.J. Baldick 1, B.J. Eggers 1, J. Fang 1, M.J. Wichroski 1,
More informationChronic Hepatitis B - Antiviral Resistance in Korea -
Chronic Hepatitis B - Antiviral Resistance in Korea - Young-Suk Lim University of Ulsan College of Medicine Asan Medical Center Seoul, Korea HBV Genome partially double-stranded DNA genome about 3200 nucleotides
More informationTerapia dell epatite cronica B: paradigmi attuali e possibili scenari futuri
Terapia dell epatite cronica B: paradigmi attuali e possibili scenari futuri Nicola Coppola Dipartimento di Salute Mentale e Medicina Preventiva Seconda Università di Napoli Main goal of treatment of chronic
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationA tale of two patients
15 th Annual Resistance and Antiviral Therapy Meeting Dr Sanjay Bhagani Royal Free Hospital, London Thursday 29 September 2011, Royal College of Physicians, London A tale of two patients Sanjay Bhagani
More informationIs there a need for combination treatment? Yes!
18.0.2012 C Hep Meeting Berlin Is there a need for combination treatment? Yes! Florian van Bömmel University Hospital Leipzig Hepatology Section Germany Most patients respond to monotherapy with entecavir
More informationOptimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta
Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationTenofovir as a drug of choice for the chronic hepatitis B treatment
EASL endorsed conference White Nights of Hepatology 2013 Symposium Perspectives of chronic viral hepatitis B and C treatment June 6-7 Saint-Petersburg Tenofovir as a drug of choice for the chronic hepatitis
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationESCMID Online Lecture Library. by author
Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues
More informationGilead Sciences, Durham, NC, USA
Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF () for Treatment of Chronic Hepatitis B (CHB) In Patients with Persistent Viral Replication Receiving Adefovir Dipivoxil: Final Week 168
More informationRecent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov
EASL endorsed conference White Nights of Hepatology 2012 Adverse events during antiviral therapy: how to predict, manage and monitor June 7-8 Saint-Petersburg Recent achievements in the treatment of hepatitis
More informationLandmarks for Prevention and Treatment
HBeAg-positive chronic hepatitis B Why do I treat my patient with a nucleos(t)ide analogue? Dr. Nancy Leung BSc(Lon) MSc(Lon) MBBS(Lon) MD(Lon), FRCP(Lon) FRCP(Edin) FHKCP FHKAM Consultant Physician, Alice
More informationHow find a solution for alternative to indefinite nucleoside analogue therapy in patients chronic HBV infection?
How find a solution for alternative to indefinite nucleoside analogue therapy in patients chronic HBV infection? Philippe Halfon, MD,PhD Associate Professor of Medicine Hôpital Europeen Marseille, France
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationHBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But
HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,
More informationViral hepatitis Prevention Board. Clinical aspects of hepatitis B
Viral hepatitis Prevention Board Clinical aspects of hepatitis B Natural History and serological markers acute and chronic hepatitis B Acute hepatitis B Immune response Immunological tolerance Resolution
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More informationNovedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
More informationTreatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia
Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute
More informationTreatment of chronic hepatitis B 2013 update
22 February 213 Treatment of chronic hepatitis B 213 update Pietro Lampertico 1st Gastroenterology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico Università di Milano EASL 212 Clinical
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationEASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection European Association for the Study of the Liver Introduction Our understanding of the natural history of hepatitis B
More informationChronic HBV Management in 2013
Chronic HBV Management in 2013 Mohammad Hossein Somi MD Professor of Gastroentrology and hepatology Liver and Gastrointestinal Disease Research Center Tabriz University of Medical Sciences 1 HBV in 2013
More informationTRANSPARENCY COMMITTEE OPINION. 8 July 2009
The legally binding text is the original French version TRAPARENCY COMMITTEE OPINION 8 July 2009 VIREAD 245 mg film-coated tablets Bottle 30 tablets (CIP: 358 500-1) Applicant: GILEAD SCIENCES Tenofovir
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationHepatitis B: Future treatment developments
Hepatitis B: Future treatment developments VIII International Update Workshop in Hepatology Curitiba, 27.08.2016 Christoph Sarrazin St. Josefs-Hospital Wiesbaden and Goethe-University, Frankfurt am Main
More informationDisclaimer. Presenter Release are for reactive use by Medical Information only internal learning/educational use only
Disclaimer Presenter Release are for reactive use by Medical Information only internal learning/educational use only Any unsolicited request from HCP must be forwarded to Medical Information Housekeeping
More informationScottish Medicines Consortium
Scottish Medicines Consortium tenofovir disoproxil (as fumarate), 245 mg film-coated tablet (Viread ) No. (479/08) Gilead Sciences 06 June 2008 The Scottish Medicines Consortium has completed its assessment
More informationNH2 N N N O N O O P O O O O O
N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationSocietà Italiana di Ematologia
Società Italiana di Ematologia Sessione Educazionale 41 Congresso Nazionale Chemioterapia nel Portatore di Virus Epatitici Fisopatologia e diagnosi Sessione Educazionale Alfredo Marzano UODU Gastroepatologia
More informationDon t interfere My first choice is always nucs!
Don t interfere My first choice is always nucs! Robert G Gish MD Professor Consultant Stanford University Medical Director, Hepatitis B Foundation Singapore Viral Hepatitis Meeting 2014 1 Disclosures Dr
More informationAntiviral Therapy 2012; 17: (doi: /IMP1945)
Antiviral Therapy 2012; 17:387 394 (doi: 10.3851/IMP1945) Original article HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine
More informationTreatment of hepatitis B
Treatment of hepatitis B Prof. Dr. Cihan Yurdaydin University of Ankara Medical School Department of Gastroenterology 2 nd CEE Meeting on Viral Hepatitis and Co-infection with HIV Bucharest, Romania, 6-7
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationWhat can the challenges we face? HBV: Long term NUC treatment
LUNCH WORKSHOP 30th January from 12:30 to 14:30 Future therapies for HBV and HDV: What can we expect? What can the challenges we face? HBV: Long term NUC treatment Massimo Levrero Cancer Research Center
More informationGish RG and AC Gadano. J Vir Hep
Treatment in Hepatitis B and C There are options! Karen F. Murray, MD Professor of Pediatrics Director, Hepatobiliary Program Seattle Children s Hepatitis B Virus Epidemiology and natural history 400
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationOur better understanding of the natural
TREATMENT OF CHRONIC HEPATITIS B: MASTERING THE BASICS ON A COMPLEX TOPIC Ke-Qin Hu, MD* ABSTRACT The availability of newer antiviral agents, as well as comprehensive treatment recommendations, has equipped
More informationUpdate on HBV Treatment
Update on HBV Treatment Calvin Q. Pan MD, FAASLD, FACG, MACP Professor of Medicine Division of Gastroenterology and Hepatology Department of Medicine, NYU Langone Health New York University School of Medicine,
More informationThe role of entecavir in the treatment of chronic hepatitis B
REVIEW The role of entecavir in the treatment of chronic hepatitis B Evangelini Dimou Vasilios Papadimitropoulos Stephanos J Hadziyannis Department of Medicine and Liver Unit, Henry Dunant Hospital, Athens,
More informationOriginal article Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy
Antiviral Therapy 0; :0 0 (doi: 0./IMP0) Original article Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy Florian van Bömmel *,
More informationNew therapeutic strategies in HBV patients
New therapeutic strategies in HBV patients Philippe HALFON MD, PhD Associate Professor of Medecine Internal Medecine and Infectious Diseases, Hopital Europeen, Marseille, France. NUC + PEG IFN, HBsAg Clearance
More informationLong-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients
ORIGINAL ARTICLE Korean J Intern Med 2015;30:32-41 Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients Hyo Jin Kim,
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Baraclude 0.5 mg film-coated tablets Baraclude 1 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Baraclude
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis B Drug: Baraclude (entecavir), Epivir (lamivudine), Hepsera (adefovir), Intron A (interferon alfa- 2b), Pegasys (peginterferon alfa-2a), Tyzeka (telbivudine),
More informationDiscontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection
Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection Dr Abid Suddle Institute of Liver Studies King s College Hospital Why consider discontinuation of NA therapy?
More informationHepatitis B Prior Authorization Policy
Hepatitis B Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationOriginal article Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B
Antiviral Therapy 2011; 16:469 477 (doi: 10.3851/IMP1772) Original article Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B Young Eun Chon 1, Seung Up Kim
More informationNew therapeutic perspectives in HBV: when to stop NAs
Liver International ISSN 1478-3223 REVIEW ARTICLE New therapeutic perspectives in HBV: when to stop NAs Cristina Perez-Cameo, Monica Pons and Rafael Esteban Liver Unit, Department of Internal Medicine,
More informationtenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd
tenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd 05 August 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationTreatment of Hepatitis B
Treatment of Hepatitis B Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Medical Director, Liver Transplantation Indiana University Health Indiana University School of
More informationClinical dilemmas in HBeAg-negative CHB
Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department
More informationentecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd
entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has
More informationBeyond the Tip of the Iceberg: Strategies to Ensure Optimal HBV Screenin g, Diagnosis, and Initial Therapy
: Strategies to Ensure Optimal HBV Screenin g, Diagnosis, and Initial Therapy Sunday, November 1, 2009 Back Bay Ballroom Sheraton Boston Hotel Boston, Massachusetts This program is supported by an educational
More informationIdentification of hepatitis B virus DNA reverse transcriptase variants associated with partial response to entecavir
Title Identification of hepatitis B virus DNA reverse transcriptase variants associated with partial response to entecavir Author(s) Wong, DKH; Fung, JYY; Lai, CL; Yuen, RMF Citation Hong Kong Medical
More informationCurrent Status of HBV and Liver Transplant
Current Status of HBV and Liver HBV as Indication for Liver ation in U.S. Significant decrease in rate of wait listing for decompensated cirrhosis since 2003 (since s) No change in rate of wait listing
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationViral hepatitis in reproductive health. Pierre Jean Malè. Training in Reproductive Health Research - Geneva 2006
Viral hepatitis in reproductive health Pierre Jean Malè Training in Reproductive Health Research - Geneva 2006 15.03.2006 HBV and HCV treatment Pierre-Jean Malè MD 15.03.2006 Global Impact of Hepatitis
More informationDual Therapy for Chronic Hepatitis B Virus
Dual Therapy for Chronic Hepatitis B Virus Hussien Elsiesy, MD, and Douglas Dieterich, MD Corresponding author Douglas Dieterich, MD Division of Liver Diseases, Mount Sinai School of Medicine, One Gustave
More informationHorizon Scanning Technology Summary. Tenofovir disoproxil fumarate for hepatitis B. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Tenofovir disoproxil fumarate for hepatitis B April 2007 This technology summary is based on information available at the time of research
More informationTitle: Off therapy durability of response to Entecavir therapy in hepatitis B e
Title: Off therapy durability of response to Entecavir therapy in hepatitis B e antigen negative chronic hepatitis B patients Wen-Juei Jeng, MD 1,3, I-Shyan Sheen, MD 1-3, Yi-Cheng Chen, MD 1,3, Chao-Wei
More informationMedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article
DOI: 10.18044/Medinform.201852.897 ISSUE 3, 2018 HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Donika Krasteva, Radosveta Tomova,
More informationHepatitis B and D Update on clinical aspects
Hepatitis B and D Update on clinical aspects B. Müllhaupt Gastroenterology and Hepatology Swiss Transplant and HPB-Center University Hospital Zurich beat.muellhaupt@usz.ch B.M. 11.11.17 Hepatitis Strategy
More informationFor now, do not stop NUCs PHC R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit
For now, do not stop NUCs PHC 2019 R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit Disclosure PI: Clinical Trials -ABBVIE -INTERCEPT -GILEAD -Novartis -BMS
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationAUSTRALIAN PRODUCT INFORMATION - BARACLUDE (ENTECAVIR)
AUSTRALIAN PRODUCT INFORMATION - BARACLUDE (ENTECAVIR) 1 NAME OF THE MEDICINE BARACLUDE entecavir BARACLUDE entecavir 2 QUALITATIVE AND QUANTITATIVE COMPOSITION BARACLUDE film coated tablets contain 0.5
More informationOff-Therapy Durability of Response to Entecavir Therapy in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients
VIRAL HEPATITIS Off-Therapy Durability of Response to Entecavir Therapy in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Wen-Juei Jeng, 1,2 I-Shyan Sheen, 1,2 Yi-Cheng Chen, 1,2 Chao-Wei
More informationHepatitis B therapy FOCUS ON VIRAL HEPATITIS. Hellan Kwon and Anna S. Lok
FOCUS ON VIRAL HEPATITIS Hepatitis B therapy Hellan Kwon and Anna S. Lok Abstract The goal of hepatitis B treatment is to prevent cirrhosis, liver decompensation and hepatocellular carcinoma. In clinical
More informationJ.C. WANG, L.L. HE, Q. CHEN 1. Introduction. Abstract. BACKGROUND: Either combination. European Review for Medical and Pharmacological Sciences
European Review for Medical and Pharmacological Sciences Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation
More information27/01/17. Post-partum ALT flare. HBV vaccine cannot protect all babies from high viral load carrier mothers
Trepo, Chan and Lok. Lancet 2014;384:2053-63 Prevalence High (>7%) Intermediate (2%-7%) Low (
More informationThe presence of hepatitis B e antigen (HBeAg) is
Assessment of Current Criteria for Primary Nonresponse in Chronic Hepatitis B Patients Receiving Entecavir Therapy Young-Joo Yang, 1 Ju Hyun Shim, 2 Kang Mo Kim, 2 Young-Suk Lim, 2 and Han Chu Lee 2 A
More informationHBV and HCV treatment update
HBV and HCV treatment update HBV Treatment Update 29 Tawesak Tanwandee, MD. Siriraj Hospital, Bangkok, Thailand Hunt CM Hepatology 2 Life Cycle of HBV in the Hepatocyte HBV-Triggered Immune Response Viral
More informationPartial virological response to entecavir in treatment-naïve patients with chronic hepatitis B
Partial virological response to entecavir in treatment-naïve patients with chronic hepatitis B Young Eun Chon Department of Medicine The Graduate School, Yonsei University Partial virological response
More informationLong-term therapy for chronic hepatitis B: Hepatitis B virus DNA suppression leading to cirrhosis reversal
bs_bs_banner doi:10.1111/jgh.12213 REVIEW Long-term therapy for chronic hepatitis B: Hepatitis B virus DNA suppression leading to cirrhosis reversal Patrick Marcellin and Tarik Asselah Service d Hépatologie,
More informationHigh efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B
The Korean Journal of Hepatology 2012;18:75-83 http://dx.doi.org/10.3350/kjhep.2012.18.1.75 pissn: 1738-222X eissn: 2093-8047 Original Article High efficacy of adefovir and entecavir combination therapy
More informationChronic infection with the hepatitis B virus (HBV)
Adding-on Versus Switching-to Adefovir Therapy in Lamivudine-Resistant HBeAg-Negative Chronic Hepatitis B Irene Rapti, 1 Evangelini Dimou, 1,2 Panayota Mitsoula, 2 and Stephanos J. Hadziyannis 1,2 We studied
More informationFor more information about the AHF and its members, please visit:
The Asian Health Foundation (AHF) is a nonprofit organization that comprises more than 40 physicians dedicated to improving the health of Asian Americans and Pacific Islanders. For more information about
More informationDepartment of Internal Medicine, Konkuk University School of Medicine, Konkuk University Hospital, Seoul, South Korea 2
Antiviral Therapy 9 1:95 993 (doi: 1.351/IMP117) Original article Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir
More informationThe advent of sensitive assays for the detection of hepatitis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2013;-:1 10 All studies published in Clinical Gastroenterology and Hepatology are embargoed until 3PM ET of the day they are published as corrected proofs on-line.
More informationcoinfected patients predicts HBsAg clearance during long term exposure to tenofovir
Measurement of serum HBsAg in HIV/HBV coinfected patients predicts HBsAg clearance during long term exposure to tenofovir Zulema Plaza 1, Antonio Aguilera 2, Alvaro Mena 3, Luz Martín-Carbonero 1, Eugenia
More informationA Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B
Curr Hepatitis Rep (2010) 9:75 90 DOI 10.1007/s11901-010-0039-1 A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B Vandana Khungar & Steven-Huy
More informationFinal Clinical Study Report. to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI463110
BMS-475 AI463 Name of Sponsor/Company: Bristol-Myers Squibb Individual Study Table Referring to the Dossier For National Authority Use Only) Name of Finished Product: Baraclude Name of Active Ingredient:
More informationHepatitis B: is there still a role for interferon?
16 January 2018 Hepatitis B: is there still a role for interferon? Pietro Lampertico Gastroenterology and Hepatology Division Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico University of Milan
More information